TIRZEPATIDE A NEW DRUG APPROACH IN DIABETES MANAGEMENT: A REVIEW
Description
ABSTRACT
Over 3,000 years ago, the ancient Egyptians discussed a condition that
was type 1 diabetes. In ancient India, people discovered that they could
use ants to test for diabetes by presented urine to them. If the ants came
near to the urine, this was a sign that it contained high sugar. They
names this condition madhumeha, which means honey urine. During
3rd century, Apollonius of Memphis called the term “diabetes. In the
5th century, people in India and China had work out that type 2
diabetes was common. In 1776 Matthew Dobson suggest that the urine
of diabetic patient had sweet taste. In 1910 Sir Edward Albert Sharpey
Schafer confirmed that diabetes developed when there was a lack of particular chemical that
produced by pancreas and he named it insulin. In 1921 Frederick Benting and Charles
worked with two other scientists to purify insulin and produced the first treatment for
diabetes. In 1936 sir harold Percival published research between type 1 and type 2 diabetes.
Type 1 -Diabetes is due to the genetic factors .The type 1 diabetes is a lifelong condition in
which body does not produce enough insulin when the blood sugar levels is high. In the
research of 2016 diabetes 5.8% of adult have diabetes in the country.
Type 2 -The type 2 diabetes is the most common form of diabetes The type 2 diabetes occurs
when a person's body no longer respond to insulin correctly. This is called insulin resistance.
In 2019, 37.3 millions peoples have diabetes and mostly type two.
This may 2022 FDA approval a drug TIRZEPATIDE (mounjaro). The medication is the first
new diabetes medications. Tirzepatide is brand new type of medication approved for treatment of type 2 diabetes. Tirzepatide is an injectable medication but it is not a form of
insulin. In this article we discuss all the effect and side-effects of this new drug.
Files
TIRZEPATIDE A NEW DRUG APPROACH IN DIABETES.pdf
Files
(434.4 kB)
Name | Size | Download all |
---|---|---|
md5:991e3144174378eaf1984fe2571b402c
|
434.4 kB | Preview Download |